Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06609863
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-20
Brief Title:
dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Intermediate and Advanced Hepatocellular Carcinoma a Prospective Phase II Study
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study intends to evaluate the efficacy and safety of drug-eluting transcatheter arterial embolization-hepatic arterial infusion chemotherapy of oxaliplatin 5-fluorouracil and leucovorin dTACE-HAIC plus Bevacizumab and Atezolizumab for patients with intermediate-advanced huge hepatocellular carcinoma
Detailed Description:
Drug-eluting transcatheter arterial embolization dTACE and hepatic arterial infusion chemotherapy HAIC of oxaliplatin 5-fluorouracil and leucovorin are effective and safe for hepatocellular carcinoma Atezolizumab Bevacizumab was superior to sorafenib in overall survival in advanced hepatocellular carcinoma The anti-VEGF combined programmed cell death protein-1 legend 1 PD-L1 inhibitor were effective and tolerable in patients with advanced hepatocellular carcinoma We aimed to describe the efficacy and safety of locoregional therapy dTACEHAIC combined with Bevacizumab and Atezolizumab inhibitor in patients with huge hepatocellular carcinoma who can not receive radical therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None